Research programme: peptide-based disruptive therapies - SignaBlok

Drug Profile

Research programme: peptide-based disruptive therapies - SignaBlok

Alternative Names: TREM-1 inhibitors - SignaBlok

Latest Information Update: 08 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SignaBlok
  • Class Peptides
  • Mechanism of Action Signal transduction pathway modulators; TREM modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lung cancer; Sepsis

Most Recent Events

  • 25 Sep 2014 SignaBlok receives SBIR grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases for development of peptide-based therapy in Rheumatoid arthritis
  • 17 Sep 2013 Preclinical trials in Lung cancer in USA (unspecified route)
  • 17 Sep 2013 Preclinical trials in Sepsis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top